A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to new data.
from Latest Science News -- ScienceDaily https://ift.tt/2QmSzBG
via IFTTT
Sunday, September 30, 2018
Bacterial therapy tolerable, shows early promise in patients with advanced solid tumors
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment